Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Christian U. Blank et al.|The Lancet Oncology|2021Cited by 389
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialNicole Basset‐Séguin, Johan Hansson, Laurent Mortier et al.|European Journal of Cancer|2017Cited by 284
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset‐Séguin, Johan Hansson, Axel Hauschild et al.|The Lancet Oncology|2015Cited by 244
Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 PatientsF. Herms, Nicole Basset‐Séguin, Jérôme Lambert et al.|Journal of Clinical Oncology|2019Cited by 69
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with CrossoverCélèste Lebbé, Brigitte Dréno, Caroline Dutriaux et al.|Cancers|2020Cited by 47